Jyong Biotech Ltd. (NASDAQ: MENS) was upgraded by analysts at Wall Street Zen to a "hold" rating.
Jyong Biotech Ltd. - Ordinary shares (MENS)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
MENS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MENS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MENS alerts
High impacting Jyong Biotech Ltd. - Ordinary shares news events
Weekly update
A roundup of the hottest topics
MENS
News
- Jyong Biotech Responds to Share Price and Volume MovementGlobeNewswire
- Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS-2 Market EntryGlobeNewswire
- Jyong Biotech Ltd. Signs Non-Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In-Licensing of Plant-Derived MCS DrugsGlobeNewswire
- Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive OutcomesGlobeNewswire
- Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech AwardsGlobeNewswire